摘要： The medical expense subsidy for intractable diseases is part of the public health system for economic aid among patients with intractable diseases in Japan. We aimed to clarify the actual status of the medical expense subsidy for intractable diseases and quality of life (QOL) between Japanese patients with inflammatory bowel disease (IBD) who receive the subsidy and patients who are ineligible for this support. [Extracted from the article]